company background image
SFY0 logo

Theriva Biologics DB:SFY0 Stock Report

Last Price

€2.42

Market Cap

€2.7m

7D

0%

1Y

-75.9%

Updated

20 Nov, 2024

Data

Company Financials +

SFY0 Stock Overview

A clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. More details

SFY0 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Theriva Biologics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Theriva Biologics
Historical stock prices
Current Share PriceUS$2.42
52 Week HighUS$14.00
52 Week LowUS$2.42
Beta1.34
11 Month Change0%
3 Month Change-0.82%
1 Year Change-75.92%
33 Year Change-96.47%
5 Year Change-97.21%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Shareholder Returns

SFY0DE BiotechsDE Market
7D0%-0.7%-0.02%
1Y-75.9%-17.2%8.2%

Return vs Industry: SFY0 underperformed the German Biotechs industry which returned -17.2% over the past year.

Return vs Market: SFY0 underperformed the German Market which returned 7.8% over the past year.

Price Volatility

Is SFY0's price volatile compared to industry and market?
SFY0 volatility
SFY0 Average Weekly Movementn/a
Biotechs Industry Average Movement6.4%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.4%

Stable Share Price: SFY0's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine SFY0's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a22Steve Shallcrosstherivabio.com

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.

Theriva Biologics, Inc. Fundamentals Summary

How do Theriva Biologics's earnings and revenue compare to its market cap?
SFY0 fundamental statistics
Market cap€2.70m
Earnings (TTM)-€25.21m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SFY0 income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$26.69m
Earnings-US$26.69m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-11.75
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.7%

How did SFY0 perform over the long term?

See historical performance and comparison